|
|
|
Business Summary: HEB
Keep Hemispherx BioPharma, Inc. HEB on your watch-list..
Hemispherx Biopharma, Inc. (Hemispherx) is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's products include Ampligen and Alferon N and Injection. Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as a vaccine enhancer(adjuvant) for both therapeutic and preventative vaccine development. Alferon N is an indicator for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is an application under early stage development targeting influenza and viral diseases. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS.
Article: More on HEB
HEB reported 1st qtr 2009 earnings of $-0.04 per share on 5/11/09. This beat the consensus of the analysts covering the company.
Ampligen
The Company's double-stranded Ribonucleic Acid (RNA) drug product, Ampligen is in human clinical development for various therapeutically oriented studies, including treatment for Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS), HIV, renal cell carcinoma and malignant melanoma.
Alferon N Injection
The Company's Alferon N Injection(R) product contains a multi-species form of alpha interferon. Alpha interferons are manufactured in three ways: by genetic engineering, by cell culture, and from human white blood cells. Alferon N Injection(R) [Interferon alfa-n3] (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.
Alferon(R) Low Dose Oral (LDO)
The Company's Alferon LDO is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon. It is an experimental immunotherapeutic stimulating an immune cascade response in the cells of the mouth and throat, enabling it to support systemic immune response through the entire body by absorption through the oral mucosa. The Company has conducted clinical trials of the experimental bio-therapeutic Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) for Avian Flu and other lethal viral diseases, which have high acute death rates.
Oragens
The Company acquired licenses for Oragens, a set of oral spectrum antivirals and immunological enhancers. The 2', 5' oligoadenylate synthetase/RNase L system is a distributed pathway for the inhibition of viral replication and tumor growth. The bioactive 2-5A molecules are degraded by various hydrolytic enzymes. Analogues of these bioactive 2-5As, termed Oragen RNA compounds, have been produced to increase stability and maintain or increase biological activity without demonstrable toxicity.
The Company competes with Gilead Pharmaceutical, Pfizer, Bristol-Myers, Abbott Labs, GlaxoSmithKline, Merck and Schering-Plough Corp.
Hemispherx Biopharma Press Release for Thursday, June 04, 2009
Japanese National Institute of Infectious Diseases Scientists Identify Hemispherx Biopharma's Drug Technology as the "Most Promising Mucosal Adjuvant for Influenza"
Topical Application Also Affords Strong Cross-Protection against Variant Flu Strains..
Philadelphia, PA, Thursday, June 04, 2009: Hemispherx Biopharma (NYSE AMEX: HEB) announced today that a new peer reviewed publication titled "Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses" was published in Therapeutics and Clinical Risk Management 2009:5 125-132. The article summarizes ongoing research in which researchers conclude that Poly I:PolyC12U (Ampligen), an experimental therapeutic, is the "most promising adjuvant candidate for mucosal vaccines." Poly I:PolyC12U (Ampligen), an experimental therapeutic, was also" extremely important" in these studies in that it produced cross-protection against variant influenza viruses not seen with the vaccines given alone.
For more information on Hemispherx BioPharma, Inc., visit their website at: http://www.hemispherx.net/
|
|
|
|
|
|
|
